文献速递腹部USCTMR

监测超声检出LI-RADS US-2阈下观察的结局

Outcomes of LI-RADS US-2 Subthreshold Observations Detected on Surveillance Ultrasound.
PubMed 文献 · AJR Am J Roentgenol · 2022-06-15

该回顾性研究纳入175例HCC高危患者监测超声检出的US-2阈下观察,随访2年以上超声或CT/MRI显示173/175最终稳定、无对应病灶或LR-1/LR-2,仅2例为LR-3,无进展至US-3或LR-4及以上;8例发生HCC但均与基线观察部位不同。

要点

  • US-2阈下观察随访2年以上多稳定、无对应病灶或LR-1/LR-2(173/175)。
  • 仅2/175随访CT/MRI分类为LR-3,无进展至US-3或LR-4及以上。
  • 8例发生HCC均位于基线观察不同部位,且此前监测超声未能再识别基线观察。

核心结论

  • US-2阈下观察不太可能进展或成为HCC,随访影像上常无对应病灶。

研究设计与样本

  • 回顾性研究,纳入175例HCC高危患者(中位年龄59岁;70例女性、105例男性)监测超声检出的US-2观察;随访超声2年及以上,随访多相CT或MRI按<2年与≥2年分层。

关键影像表现/征象

  • 随访超声2年及以上:68例观察保持稳定(仍为亚厘米)。
  • 随访超声、CT或MRI:88例无对应病灶。
  • 随访CT或MRI:17例分类为LR-1或LR-2。
  • 随访CT或MRI:2例分类为LR-3。
  • 随访CT或MRI:无观察分类为LR-4及以上,随访超声无观察进展至US-3。

诊断标准与关键数值

  • US-2观察定义为监测超声上的亚厘米观察。
  • 随访超声2年及以上分类:无对应病灶、稳定(仍为亚厘米)或进展(测量≥10 mm,符合US-3标准)。
  • 随访多相CT或MRI按CT/MRI LI-RADS 2018版分类。
  • 106例随访CT或MRI中25例见对应病灶:23例为LR-1或LR-2,2例为LR-3。

临床应用与阅片要点

  • US-2阈下观察随访多无对应病灶或为良性(LR-1/LR-2),仅少数为LR-3。
  • 8例HCC均位于基线观察不同部位,且此前监测超声未能再识别基线观察。
  • 3例肝移植患者移植肝病理未见异型增生结节或HCC。
  • 因US-2进展率低,作者认为多个专业学会推荐的延长强化监测是否有必要尚不明确。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Ultrasound LI-RADS version 2017 recommends that patients with US-2 subthreshold observations undergo repeat surveillance ultrasound in 3-6 months and return to routine surveillance if the observation shows no growth for 2 years. However, outcomes of US-2 observations are unknown. OBJECTIVE. The purpose of this article was to determine imaging outcomes of US-2 observations detected on surveillance ultrasound examinations. METHODS. This retrospective study included 175 patients (median age, 59 years; 70 women, 105 men) at high risk for hepatocellular carcinoma (HCC) with US-2 observations (i.e., subcentimeter observations) on surveillance ultrasound. Observations were classified on follow-up ultrasound performed 2 or more years later as showing no correlate, stable (if remaining subcentimeter), or progressed (if measuring ≥ 10 mm, meeting US-3 criteria). Observations were classified on follow-up multiphasic CT or MRI (stratified as < 2-year vs ≥ 2-year follow-up) as showing no correlate or, if showing a correlate, using CT/MRI LI-RADS version 2018. RESULTS. A total of 111 patients had follow-up ultrasound after 2 or more years and 106 had follow-up CT or MRI (79 before 2 years, 27 after 2 years). On the basis of final follow-up examinations, 173 of 175 observations were stable on follow-up ultrasound 2 or more years later (n = 68); showed no correlate on follow-up ultrasound, CT, or MRI (n = 88); or were classified as LR-1 or LR-2 on CT or MRI (n = 17). The remaining 2 of 175 observations were LR-3 on CT or MRI. No observations progressed to US-3 on follow-up ultrasound or were classified as LR-4 or greater on CT or MRI. A correlate was observed in 25 of the 106 follow-up CT or MRI examinations (LR-1 or LR-2 in 23; LR-3 in two). Eight patients developed HCC at a median of 2.0 years after initial US-2 observation detection; all HCCs were in separate locations from the baseline observations and were preceded by a surveillance ultrasound that could not reidentify the baseline observation. In three patients who underwent liver transplant, the explant showed no dysplastic nodule or HCC. CONCLUSION. US-2 subthreshold observations are unlikely to progress or become HCC and commonly have no correlate on follow-up imaging. CLINICAL IMPACT. Because of the low progression rate of US-2 subthreshold observations, it is unclear if an extended period of intensive surveillance, as recommended by multiple professional societies, is warranted.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Tse, Shen, Bird, et al. Outcomes of LI-RADS US-2 Subthreshold Observations Detected on Surveillance Ultrasound. AJR Am J Roentgenol. 2022. PMID: 35703411. doi:10.2214/AJR.22.27812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。